Latest / Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Semaglutide 2.4 mg (Wegovy):A Turning Point for Obesity
Ahead of ADA 2021, Dr. Thomas Wadden discusses the significance of the Wegovy approval for chronic weight management and Novo Nordisk's plans to evaluate an oral version.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.